Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cervical Cancer
Landmark Study in the New England Journal of Medicine Shows HPV Testing Significantly Reduces Deaths from Cervical Cancer, Compared to other Methods Including Pap
April 14th, 2009
Results from an eight-year trial involving more than 130,000 women published in The New England Journal of Medicine (NEJM) demonstrate that in low-resource settings a single round of HPV testing significantly reduces the numbers of advanced cervical cancers and deaths, compared with Pap (cytology) testing or visual inspection with acetic acid (VIA). The trial used QIAGEN's (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) digene HPV Test, which detects high-risk types of human papillomavirus that cause cervical cancer. "The implications of the findings of this trial are immediate and global: international experts in cervical-cancer prevention should now adapt HPV testing...
Source: Cancer Weekly (2009-04-14)
|
